Literature DB >> 32224276

Ethical outpatient dermatology care during the coronavirus (COVID-19) pandemic.

James T Pathoulas1, Benjamin K Stoff2, Kachiu C Lee3, Ronda S Farah4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32224276      PMCID: PMC7195559          DOI: 10.1016/j.jaad.2020.03.047

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   15.487


× No keyword cloud information.
—Dr Concerned About Coronavirus As of March 17, a total of 179,111 confirmed COVID-19 cases have been reported to the World Health Organization, 3503 of which are within the United States. The coronavirus has broad virulence and a 14-day latent period, making risk of viral transmission and subsequent illness high. In the outpatient setting, dermatologists are challenged with upholding seemingly competing professional duties. For example, triaging a patient who requires urgent in-person evaluation but is at high-risk of COVID-19 transmission or illness illustrates the current moral dilemma facing dermatologists. Values also conflict when the very measures that protect staff and others from infection threaten employee salary and practice solvency. Dermatologists at West China Hospital, located in a province hard-hit by 2019-nCoV, initially closed outpatient clinics and cancelled elective operations. As the pandemic progressed, they resumed outpatient office visits and operations on a case-by-case basis. The timeframe of return to outpatient services and triage decision-making strategies were not described. Similarly, some dermatologists in the United States have temporarily closed their practices to reduce transmission risk. From a public health standpoint, the decision to temporarily close a practice is reasonable. It reduces infection risk not only for patients, staff, and providers but also for others in contact with them. However, closing practices prevents providers from delivering needed care and has financial consequences for the practice and staff. Teledermatology permits consultation without increased risk of infection, is cost-effective, and provides accurate diagnostic information. Providers can use teledermatology for routine follow-up appointments and to triage individual patients for emergency in-person care. Providers who have temporarily ceased in-person visits could transfer most visits to teledermatology. Regulatory and reimbursement requirements for telemedicine have eased substantially during the pandemic. Not all patients, however, have the desire, skills, or technology to engage in teledermatology and may have dermatologic problems that are not amenable to telemedicine. Elderly patients, for example, may be unable to participate in teledermatology but are at high-risk for COVID-19 infection and dermatologic emergencies that require in-person care. Despite these limitations, teledermatology is a useful tool for providing adequate outpatient care for many patients during the pandemic. Significantly reducing office-based, in-person services while increasing teledermatology consultation has the potential to permit effective and reimbursable dermatologic care that also upholds public health. Keeping patients with dermatologic conditions out of overwhelmed emergency rooms and urgent cares, where the risk of contracting or spreading COVID-19 may be high, is critical. Ultimately, dermatologists will need to determine what warrants an urgent office visit during the pandemic. Dermatologists should weigh the potential harm of delaying an in-person visit against the potential harm of COVID-19 infection to the patient, practice, and community. We argue that only those cases in which the delay of in-person care exceeds the risk of COVID-19 infection should be considered for evaluation in the office during the pandemic. —Dr Dermatoethicist
  3 in total

Review 1.  Teledermatology for diagnosis and management of skin conditions: a systematic review.

Authors:  Erin M Warshaw; Yonatan J Hillman; Nancy L Greer; Emily M Hagel; Roderick MacDonald; Indulis R Rutks; Timothy J Wilt
Journal:  J Am Acad Dermatol       Date:  2010-10-30       Impact factor: 11.527

2.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Authors:  Sebastian Hoehl; Holger Rabenau; Annemarie Berger; Marhild Kortenbusch; Jindrich Cinatl; Denisa Bojkova; Pia Behrens; Boris Böddinghaus; Udo Götsch; Frank Naujoks; Peter Neumann; Joscha Schork; Petra Tiarks-Jungk; Antoni Walczok; Markus Eickmann; Maria J G T Vehreschild; Gerrit Kann; Timo Wolf; René Gottschalk; Sandra Ciesek
Journal:  N Engl J Med       Date:  2020-02-18       Impact factor: 91.245

3.  What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus?

Authors:  Yusha Chen; Sushmita Pradhan; Siliang Xue
Journal:  J Am Acad Dermatol       Date:  2020-02-17       Impact factor: 11.527

  3 in total
  6 in total

1.  The impact of COVID-19 on the new diagnoses of melanoma.

Authors:  Christophe Gedeah; Thomas Damsin; Gilles Absil; Joan Somja; Patrick Collins; Andrée Rorive; Nathalie Marchal; Laurence Seidel; Arjen F Nikkels
Journal:  Eur J Dermatol       Date:  2021-08-01       Impact factor: 2.805

Review 2.  The Multifaceted Engagement of the Dermatologist in the Covid-19 Pandemic.

Authors:  Boutros Soutou; Roland Tomb
Journal:  SN Compr Clin Med       Date:  2020-07-22

Review 3.  Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.

Authors:  Fahimeh Abdollahimajd; Mohammad Shahidi-Dadras; Reza M Robati; Sahar Dadkhahfar
Journal:  Arch Acad Emerg Med       Date:  2020-04-18

4.  Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.

Authors:  William J Nahm; Eran C Gwillim; Evangelos V Badiavas; Anna J Nichols; Robert S Kirsner; Laurence H Boggeln; John T Shen
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-17

Review 5.  Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era.

Authors:  Seyyede Zeinab Azimi; Alireza Firooz; Dedee F Murrell; Maryam Daneshpazhooh
Journal:  Dermatol Ther       Date:  2020-07-25       Impact factor: 3.858

Review 6.  COVID-19 and dermatology: a comprehensive guide for dermatologists.

Authors:  D H Fahmy; H S El-Amawy; M A El-Samongy; A A Fouda; S H Soliman; A El-Kady; F Farnetani; A Conti; A Zoeir; A Eissa; R Eissa; S Puliatti; M C Sighinolfi; B Rocco; G Pellacani
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-10       Impact factor: 9.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.